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Aim. The hippocampus is believed to play a crucial role in seizure generation in temporal lobe epilepsy 
(TLE), a common form of medication-resistant epilepsy. This preclinical study evaluated chemogenetics 
as a potential therapy for TLE. Using this approach, excitatory neurons of the epileptic hippocampus 
were selectively inhibited through ligand-based activation of an inhibitory Designer Receptor 
Exclusively Activated by Designer Drugs (DREADD).  
Methods. The intraperitoneal kainic acid rat model for TLE was used. Animals (n=6) were injected in 
right hippocampus with adeno-associated viral vector carrying CamKIIα-hM4Di-mCherry. Two weeks 
after injection, rats were bilaterally implanted with depth electrodes in the dentate gyrus and CA1 
region of both hippocampi. Seizure frequency before and after activating DREADDs with subclinical 
doses of clozapine was determined using continuous video-EEG recordings. 
First, EEG was monitored during a baseline period of six days. Next, single injections of different 
clozapine doses (0.01, 0.1 or 1 mg/kg bodyweight/24h, s.c.) and vehicle were compared. For each dose, 
EEG was monitored during three days of treatment. Finally, one dose was selected to evaluate an 
improved dosing scheme in a randomized-blind trial. EEG was monitored during a baseline period of 
one days, followed by one day of treatment with clozapine (0.1mg/kg bodyweight/6h) or vehicle. In all 
experiments, seizure frequency during baseline recordings was used to normalize the data.  
Results. Clozapine-induced activation of DREADDs had a dose-dependent seizure suppressing effect.  
Clozapine doses of 0.01, 0.1 and 1 mg/kg resulted in a clear lag in average cumulative seizure frequency 
of about 2, 5 and 8 hours respectively. Repeated clozapine administration resulted in a strong 
suppression of epileptic seizures in all animals tested. During treatment, the average daily seizure 
frequency was reduced with 86%±7% (SEM).  
Conclusion. Clozapine-mediated activation of hM4Di DREADDs in excitatory hippocampal neurons 
temporary suppresses spontaneous seizures in a rat model for TLE in a dose-dependent way. Repeated 
clozapine administration results in a sustained suppression of epileptic seizures. 
 
